Loreto Fernández‐González
Biographic Data
| ID | 7690481 |
|---|---|
| NAME | Loreto Fernández‐González |
| GIVEN NAMES | Loreto |
| FAMILY NAME | Fernández‐González |
| SIGNATURE | GONZÁLEZ L F |
| AFFILIATIONS | University of Toronto |
| ORCID | 0000-0001-5026-6438 |
| VERIFIED | Yes |
| TOTAL WORKS | 4 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 4 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Seizing the opportunity
Background In oncology, the standard of care (SoC) is rapidly evolving, and increasingly unaffordable, prompting both patients and providers to enroll in commercial clinical trials as a means to access the SoC. The experiences of trial participants and their providers in Latin America remain largely unknown. We report their experiences and relationships of care(giving) within the trial in a cancer center in Santiago, Chile. We examine how the gap…
“If I am here, it is because the system failed”
BACKGROUND: The pharmaceutical industry is a key global health actor given its crucial role in the development and testing of medicines. Within Latin America, Chile currently has the highest number of multinational commercial clinical trials per inhabitant, predominantly for oncological therapies. Insufficient attention has been paid to context-specific conditions that enable clinical trials' successful implementation in the Global South. In exam…
Registering transparency
BACKGROUND: This paper examines the events and conditions that led to the creation of the International Clinical Trials Registry Platform (ICTRP) in 2006 by the World Health Organization (WHO), and how the WHO addressed the issue of transparency in global pharmaceutical research. Using historical textual analysis, I trace the scientific debates that advocated for the establishment of official clinical trial registries in medical journals, and the…
Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Mod…
For determining MIDs of the remaining scales of the EORTC QLQ-HN43, we will omit comparisons of groups based on the Karnofsky Performance Score. Other external anchors are needed instead. Distribution-based methods worked well and will be applied as a starting strategy for analyses. For the calculation of MICs, subjective change ratings, predictive modelling, and standard-deviation based approaches are suitable methods whereas ROC analyses seem t…
No prominent works on this page.
Methodological approach for determining the Minimal Important Difference and Minimal Important Change scores for the European Organisation for Research and Treatment of Cancer Head and Neck Cancer Mod…
For determining MIDs of the remaining scales of the EORTC QLQ-HN43, we will omit comparisons of groups based on the Karnofsky Performance Score. Other external anchors are needed instead. Distribution-based methods worked well and will be applied as a starting strategy for analyses. For the calculation of MICs, subjective change ratings, predictive modelling, and standard-deviation based approaches are suitable methods whereas ROC analyses seem t…
Registering transparency
BACKGROUND: This paper examines the events and conditions that led to the creation of the International Clinical Trials Registry Platform (ICTRP) in 2006 by the World Health Organization (WHO), and how the WHO addressed the issue of transparency in global pharmaceutical research. Using historical textual analysis, I trace the scientific debates that advocated for the establishment of official clinical trial registries in medical journals, and the…
“If I am here, it is because the system failed”
BACKGROUND: The pharmaceutical industry is a key global health actor given its crucial role in the development and testing of medicines. Within Latin America, Chile currently has the highest number of multinational commercial clinical trials per inhabitant, predominantly for oncological therapies. Insufficient attention has been paid to context-specific conditions that enable clinical trials' successful implementation in the Global South. In exam…
Seizing the opportunity
Background In oncology, the standard of care (SoC) is rapidly evolving, and increasingly unaffordable, prompting both patients and providers to enroll in commercial clinical trials as a means to access the SoC. The experiences of trial participants and their providers in Latin America remain largely unknown. We report their experiences and relationships of care(giving) within the trial in a cancer center in Santiago, Chile. We examine how the gap…
Cancer (3 works) · Clinical trial (3 works) · Ethics in Clinical Research (3 works) · Alternative medicine (2 works) · Biomedical Ethics and Regulation (2 works) · Economic and Financial Impacts of Cancer (2 works) · Medicine (2 works) · Public health (2 works) · Qualitative research (2 works) · Quality of Life Research (2 works)